Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does GLIMEPIRIDE Cause Myocardial infarction? 46 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 46 reports of Myocardial infarction have been filed in association with GLIMEPIRIDE (Glimepiride). This represents 0.8% of all adverse event reports for GLIMEPIRIDE.

46
Reports of Myocardial infarction with GLIMEPIRIDE
0.8%
of all GLIMEPIRIDE reports
5
Deaths
31
Hospitalizations

How Dangerous Is Myocardial infarction From GLIMEPIRIDE?

Of the 46 reports, 5 (10.9%) resulted in death, 31 (67.4%) required hospitalization, and 5 (10.9%) were considered life-threatening.

Is Myocardial infarction Listed in the Official Label?

Yes, Myocardial infarction is listed as a known adverse reaction in the official FDA drug label for GLIMEPIRIDE.

What Other Side Effects Does GLIMEPIRIDE Cause?

Hypoglycaemia (1,403) Blood glucose increased (446) Acute kidney injury (339) Drug ineffective (339) Diarrhoea (257) Blood glucose decreased (232) Lactic acidosis (219) Glycosylated haemoglobin increased (214) Diabetes mellitus inadequate control (213) Hypoglycaemic coma (187)

What Other Drugs Cause Myocardial infarction?

ROSIGLITAZONE (17,018) TESTOSTERONE (3,396) ADALIMUMAB (3,214) SACUBITRIL\VALSARTAN (3,120) CALCIUM\DEXTROSE\MAGNESIUM\SODIUM\SODIUM (2,391) APIXABAN (2,010) TICAGRELOR (1,749) LENALIDOMIDE (1,712) ETANERCEPT (1,693) METFORMIN\ROSIGLITAZONE (1,640)

Which GLIMEPIRIDE Alternatives Have Lower Myocardial infarction Risk?

GLIMEPIRIDE vs GLIMEPIRIDE\ROSIGLITAZONE GLIMEPIRIDE vs GLIPIZIDE GLIMEPIRIDE vs GLIVEC GLIMEPIRIDE vs GLOFITAMAB GLIMEPIRIDE vs GLOFITAMAB-GXBM

Related Pages

GLIMEPIRIDE Full Profile All Myocardial infarction Reports All Drugs Causing Myocardial infarction GLIMEPIRIDE Demographics